Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
French cancer focused biotech Transgene has appointed two seasoned leaders in oncology who will be instrumental in advancing the company’s innovative immunotherapy programs 10 September 2024
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024
US clinical-stage biotech IDRx today announced that it has strengthened its leadership team with the appointments of Tim Clackson, as chief executive and Brad Dahms as chief financial officer and chief business officer. 12 March 2024
US retinal disease specialist Apellis Pharmaceuticals today announced that Dr Philip Ferrone will join the company as chief medical retina advisor, effective March 18. 11 March 2024
OncoNano Medicine, a biotech company that develops pH-activated compounds that digitalize and exploit the variability of pH in disease, has named Kartik Krishnan its new chief executive and member of the board of directors. 1 March 2024
US clinical-stage cell therapy developer Vittoria Biotherapeutics today said that accomplished life sciences leader, Rosemary Mazanet, has joined the company as chief medical officer. 27 February 2024
US hematology specialist Disc Medicine today announced the appointment of Pamela Stephenson as the company’s chief commercial officer. 26 February 2024
Ophthalmology company Ocular Therapeutix has named what it describes as a ‘retina dream team’ alongside its announcement of a $325 million financing. 23 February 2024
USA-based biotech Emergent BioSolutions has appointed Joseph Papa as president and chief executive (CEO), effective February 21, 2024. 22 February 2024
PolTREG, a Polish biotech developing cell therapies for autoimmune diseases, has named Daniel Shelly its chief business development officer. 21 February 2024
After four years in stealth, California, USA-based biotech Latigo Biotherapeutics today announced its emergence with a $135 million Series A financing. 14 February 2024
Privately-held French biotech StromaCare, which is developing immunotherapies through stroma modulation, today announced the appointment of Georges Rawadi as chief executive (CEO). 13 February 2024
Neuropsychologist Dr Paul Wicks joins the ranks of Cambridge, UK-based precision medicine scaleup Sano Genetics today, where he will take up the full-time role of vice president of neuroscience. 5 February 2024
OneChain Immunotherapeutics (OCI), a Spanish biotech focused on the development of CAR-T therapies for the treatment of oncologic diseases, has named Stefanos Theoharis as the company's new chief executive. 1 February 2024
US clinical-stage biotech Remix Therapeutics today announced the appointment of Dominic Reynolds, as its chief scientific officer (CSO). 1 February 2024
Danish biotech Ascendis Pharma today announced the formation and launch with Frazier Life Sciences of Eyconis Inc, a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally. 30 January 2024
Osivax, a French biopharma developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, has named Nicola Groth its new chief medical officer (CMO). 26 January 2024
Cellular Origins, a part of TTP Company, focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies, today announced the appointment of Peter Crossley as chief operating officer (COO). 25 January 2024